Streamlining Clinical Trials for Enhanced Patient Care and Collaboration
Massive Bio, a leading provider of personalized oncology solutions, will be participating in the prestigious American Society of Clinical Oncology (ASCO) annual meeting from June 2nd to June 6th. The event serves as a platform for sharing groundbreaking advancements in cancer care, and Massive Bio is excited to unveil its innovative ChatGPT-powered chatbot platform featuring AskFiona AI and DrArturo AI.
The ChatGPT-powered chatbot platform developed by Massive Bio aims to revolutionize how cancer patients, referring physicians, and site principal investigators access and interact with clinical trial information. With AskFiona AI as the initial point of contact, patients can receive comprehensive insights into clinical trials, understanding their purpose and assessing eligibility. The platform seamlessly escalates patients to DrArturo AI, providing tailored information about specific clinical trials, including treatment details, schedules, nearest treatment facilities, and more.
Massive Bio’s presence at ASCO 2023 highlights their commitment to driving progress in cancer treatment and improving patient care. Don’t miss the opportunity to explore their groundbreaking innovations firsthand. You can see more details in soon.
